Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9606 |
High Similarity |
NPD3027 |
Phase 3 |
0.8947 |
High Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.8947 |
High Similarity |
NPD1613 |
Approved |
0.8647 |
High Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.8571 |
High Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.8268 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.8235 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.8224 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.8134 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.8134 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.8133 |
Intermediate Similarity |
NPD37 |
Approved |
0.8129 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.8129 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.812 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.8116 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.811 |
Intermediate Similarity |
NPD228 |
Approved |
0.8092 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.8092 |
Intermediate Similarity |
NPD4965 |
Approved |
0.8092 |
Intermediate Similarity |
NPD4966 |
Approved |
0.806 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.8029 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.8029 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.8013 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7985 |
Intermediate Similarity |
NPD3705 |
Approved |
0.7975 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7953 |
Intermediate Similarity |
NPD3021 |
Approved |
0.7953 |
Intermediate Similarity |
NPD3022 |
Approved |
0.7868 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7857 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7843 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7823 |
Intermediate Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.782 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.7771 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7761 |
Intermediate Similarity |
NPD1357 |
Approved |
0.775 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7748 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7737 |
Intermediate Similarity |
NPD4749 |
Approved |
0.7736 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7736 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7736 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.773 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.7727 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7698 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7687 |
Intermediate Similarity |
NPD4237 |
Approved |
0.7687 |
Intermediate Similarity |
NPD4236 |
Phase 3 |
0.7677 |
Intermediate Similarity |
NPD6374 |
Clinical (unspecified phase) |
0.7671 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.766 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.7628 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7622 |
Intermediate Similarity |
NPD1558 |
Phase 1 |
0.7622 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7597 |
Intermediate Similarity |
NPD2684 |
Approved |
0.7594 |
Intermediate Similarity |
NPD7157 |
Approved |
0.7582 |
Intermediate Similarity |
NPD6055 |
Clinical (unspecified phase) |
0.7582 |
Intermediate Similarity |
NPD4005 |
Discontinued |
0.758 |
Intermediate Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.7568 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7568 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7568 |
Intermediate Similarity |
NPD3060 |
Approved |
0.7562 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7546 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7534 |
Intermediate Similarity |
NPD5588 |
Approved |
0.7533 |
Intermediate Similarity |
NPD7124 |
Phase 2 |
0.7532 |
Intermediate Similarity |
NPD4678 |
Approved |
0.7532 |
Intermediate Similarity |
NPD4675 |
Approved |
0.75 |
Intermediate Similarity |
NPD7843 |
Approved |
0.75 |
Intermediate Similarity |
NPD2238 |
Phase 2 |
0.75 |
Intermediate Similarity |
NPD2977 |
Approved |
0.75 |
Intermediate Similarity |
NPD2978 |
Approved |
0.7485 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7484 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7483 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7483 |
Intermediate Similarity |
NPD4357 |
Discontinued |
0.7483 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7482 |
Intermediate Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.7466 |
Intermediate Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.7466 |
Intermediate Similarity |
NPD4536 |
Approved |
0.7466 |
Intermediate Similarity |
NPD4538 |
Approved |
0.7464 |
Intermediate Similarity |
NPD1091 |
Approved |
0.7455 |
Intermediate Similarity |
NPD7240 |
Approved |
0.745 |
Intermediate Similarity |
NPD5177 |
Phase 3 |
0.7448 |
Intermediate Similarity |
NPD5735 |
Approved |
0.7439 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7432 |
Intermediate Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.7432 |
Intermediate Similarity |
NPD3540 |
Phase 1 |
0.7419 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7417 |
Intermediate Similarity |
NPD5058 |
Phase 3 |
0.74 |
Intermediate Similarity |
NPD6331 |
Phase 2 |
0.74 |
Intermediate Similarity |
NPD3892 |
Phase 2 |
0.74 |
Intermediate Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.74 |
Intermediate Similarity |
NPD4110 |
Phase 3 |
0.7386 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7378 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7376 |
Intermediate Similarity |
NPD3094 |
Phase 2 |
0.7365 |
Intermediate Similarity |
NPD3539 |
Phase 1 |
0.7361 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7353 |
Intermediate Similarity |
NPD5536 |
Phase 2 |
0.7351 |
Intermediate Similarity |
NPD6190 |
Approved |
0.7347 |
Intermediate Similarity |
NPD6111 |
Discontinued |
0.7342 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7338 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7329 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7329 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7323 |
Intermediate Similarity |
NPD1242 |
Phase 1 |
0.7321 |
Intermediate Similarity |
NPD7090 |
Clinical (unspecified phase) |
0.7315 |
Intermediate Similarity |
NPD5762 |
Approved |
0.7315 |
Intermediate Similarity |
NPD1375 |
Discontinued |
0.7315 |
Intermediate Similarity |
NPD5763 |
Approved |
0.7305 |
Intermediate Similarity |
NPD8651 |
Approved |
0.7297 |
Intermediate Similarity |
NPD5960 |
Phase 3 |
0.7289 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7285 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7284 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7279 |
Intermediate Similarity |
NPD6653 |
Approved |
0.7278 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7273 |
Intermediate Similarity |
NPD4750 |
Phase 3 |
0.7256 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7252 |
Intermediate Similarity |
NPD290 |
Approved |
0.7248 |
Intermediate Similarity |
NPD2161 |
Phase 2 |
0.7246 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7244 |
Intermediate Similarity |
NPD3020 |
Approved |
0.7241 |
Intermediate Similarity |
NPD5111 |
Phase 2 |
0.7241 |
Intermediate Similarity |
NPD5109 |
Approved |
0.7241 |
Intermediate Similarity |
NPD5110 |
Phase 2 |
0.7237 |
Intermediate Similarity |
NPD2219 |
Phase 1 |
0.7237 |
Intermediate Similarity |
NPD2677 |
Approved |
0.7233 |
Intermediate Similarity |
NPD2563 |
Approved |
0.7233 |
Intermediate Similarity |
NPD2560 |
Approved |
0.7219 |
Intermediate Similarity |
NPD1652 |
Phase 2 |
0.7219 |
Intermediate Similarity |
NPD4162 |
Approved |
0.7214 |
Intermediate Similarity |
NPD3092 |
Approved |
0.7214 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.7211 |
Intermediate Similarity |
NPD5124 |
Phase 1 |
0.7211 |
Intermediate Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.7211 |
Intermediate Similarity |
NPD3657 |
Discovery |
0.7208 |
Intermediate Similarity |
NPD4123 |
Phase 3 |
0.7206 |
Intermediate Similarity |
NPD6671 |
Approved |
0.7203 |
Intermediate Similarity |
NPD6584 |
Phase 3 |
0.7202 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7202 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7195 |
Intermediate Similarity |
NPD2489 |
Approved |
0.7195 |
Intermediate Similarity |
NPD27 |
Approved |
0.7194 |
Intermediate Similarity |
NPD6516 |
Phase 2 |
0.7194 |
Intermediate Similarity |
NPD5846 |
Approved |
0.7194 |
Intermediate Similarity |
NPD5126 |
Approved |
0.7194 |
Intermediate Similarity |
NPD5125 |
Phase 3 |
0.7192 |
Intermediate Similarity |
NPD2674 |
Phase 3 |
0.7186 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7176 |
Intermediate Similarity |
NPD968 |
Approved |
0.7172 |
Intermediate Similarity |
NPD7095 |
Approved |
0.717 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.717 |
Intermediate Similarity |
NPD5773 |
Approved |
0.717 |
Intermediate Similarity |
NPD5772 |
Approved |
0.7163 |
Intermediate Similarity |
NPD2231 |
Phase 2 |
0.7163 |
Intermediate Similarity |
NPD2235 |
Phase 2 |
0.7161 |
Intermediate Similarity |
NPD7527 |
Clinical (unspecified phase) |
0.7161 |
Intermediate Similarity |
NPD5261 |
Clinical (unspecified phase) |
0.7161 |
Intermediate Similarity |
NPD1940 |
Clinical (unspecified phase) |
0.7161 |
Intermediate Similarity |
NPD52 |
Approved |
0.7161 |
Intermediate Similarity |
NPD7526 |
Approved |
0.7143 |
Intermediate Similarity |
NPD7685 |
Pre-registration |
0.7143 |
Intermediate Similarity |
NPD7212 |
Phase 2 |
0.7143 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7143 |
Intermediate Similarity |
NPD4140 |
Approved |
0.7143 |
Intermediate Similarity |
NPD7213 |
Phase 3 |
0.7143 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7135 |
Intermediate Similarity |
NPD4663 |
Approved |
0.7134 |
Intermediate Similarity |
NPD2969 |
Approved |
0.7134 |
Intermediate Similarity |
NPD2970 |
Approved |
0.7133 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7133 |
Intermediate Similarity |
NPD6099 |
Approved |
0.7132 |
Intermediate Similarity |
NPD846 |
Approved |
0.7132 |
Intermediate Similarity |
NPD940 |
Approved |
0.7132 |
Intermediate Similarity |
NPD291 |
Approved |
0.7124 |
Intermediate Similarity |
NPD5241 |
Discontinued |
0.7123 |
Intermediate Similarity |
NPD3144 |
Approved |
0.7123 |
Intermediate Similarity |
NPD3145 |
Approved |
0.7119 |
Intermediate Similarity |
NPD7237 |
Clinical (unspecified phase) |
0.7113 |
Intermediate Similarity |
NPD5327 |
Phase 3 |
0.7103 |
Intermediate Similarity |
NPD5752 |
Clinical (unspecified phase) |
0.7101 |
Intermediate Similarity |
NPD7549 |
Discontinued |
0.7097 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7097 |
Intermediate Similarity |
NPD7447 |
Phase 1 |
0.7097 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7097 |
Intermediate Similarity |
NPD4160 |
Clinical (unspecified phase) |
0.7086 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.7086 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.7075 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7075 |
Intermediate Similarity |
NPD1726 |
Clinical (unspecified phase) |
0.7073 |
Intermediate Similarity |
NPD3051 |
Approved |
0.707 |
Intermediate Similarity |
NPD3687 |
Approved |
0.707 |
Intermediate Similarity |
NPD3686 |
Approved |
0.7067 |
Intermediate Similarity |
NPD6028 |
Clinical (unspecified phase) |
0.7067 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.7067 |
Intermediate Similarity |
NPD6029 |
Clinical (unspecified phase) |
0.7063 |
Intermediate Similarity |
NPD6696 |
Suspended |
0.7063 |
Intermediate Similarity |
NPD6818 |
Clinical (unspecified phase) |
0.7059 |
Intermediate Similarity |
NPD7466 |
Approved |
0.7059 |
Intermediate Similarity |
NPD7313 |
Approved |
0.7059
|
Intermediate Similarity |
NPD4577 |
Approved |